SCHEMBL3278864

SCHEMBL3278864

CC1C2CCC1C(C(=O)O)C2C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.42
TDP1 Q9NUW8 3/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
KDM4E B2RXH2 2/20 0.40
LMNA P02545 2/20 0.40
APEX1 P27695 1/20 0.40
GMNN O75496 1/20 0.40
PMP22 Q01453 1/20 0.40
TFPI2 P48307 1/20 0.40
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
THPO P40225 1/20 0.40
GRM2 Q14416 4/20 0.38
GRM3 Q14832 4/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SLC1A2 P43004 2/20 0.36
SLC1A1 P43005 1/20 0.36
PPP5C P53041 1/20 0.35
ALDH1A1 P00352 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19285911 0.90 POLB (0.39) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL430822 0.82 POLB (0.48) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL15646255 0.79 POLB (0.46) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL25472592 0.79 POLB (0.39) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL24197654 0.79 POLB (0.39) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL19688947 0.79 POLB (0.31) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL12763440 0.78 POLB (0.48) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL12231001 0.76 POLB (0.48) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL14972663 0.74 POLB (0.42) POLBTDP1CTDSP1KDM4ELMNA
SCHEMBL10066840 0.72 POLB (0.38) POLBTDP1CTDSP1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700802-B2 by utilizing the difference in solubility between a neutralized salt of the endo isomer and a neutral salt of the exo isomer of a dicarboxylic acid having a norbornene or norbornane structure; mixing the above endo and exo mixture with NaOH and a solvent, filtering to separate liquid and solid phase HITACHI CHEMICAL CO., LTD. (JP) 2010-04-20 US disclosed
US-20070142668-A1 Method of separating stereoisomers of dicarboxylic acid having norbornene or norbornane structure, or derivative thereof HITACHI CHEMICAL CO., LTD. (JP) 2007-06-21 US disclosed
EP-1669342-A1 METHOD OF SEPARATING STEREOISOMERS OF NORBORNENE, DICARBOXYLIC ACID HAVING NORBORNANE STRUCTURE, OR DERIVATIVE THEREOF Hitachi Chemical Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142668-A1 Method of separating stereoisomers of dicarboxylic acid having norbornene or norbornane structure, or derivative thereof EXOC1, RER1, PRMT8 POLB 2359/4885TDP1 1005/4885CTDSP1 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.